Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids

Vivien Koh1, Jayati Chakrabarti2, Meaghan Torvund2

  • 1National University Cancer Institute Singapore, National University Health System, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore.

Cancer Letters
|June 14, 2021
PubMed

Insights

Gastric cancer immunotherapy is limited by PD-L1 expression. This study reveals the mTOR pathway drives PD-L1 via Hedgehog signaling, offering new therapeutic targets for gastric tumors.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Gastric cancer exhibits low immunotherapy response due to PD-L1 expression inhibiting T cells.
  • Helicobacter pylori infection induces PD-L1 via Hedgehog (Hh) signaling in gastric epithelium.
  • The PI3K/AKT/mTOR pathway is activated in gastric cancer and influences immune responses.

Purpose of the Study:

  • To investigate if Hh signaling mediates mTOR-induced PD-L1 expression in gastric cancer.
  • To explore the role of myeloid-derived suppressor cells (MDSCs) in gastric cancer immunosuppression.
  • To evaluate patient-derived organoids (PDOs) as a model for studying tumor-immune interactions.

Main Methods:

  • Generated PDOs from gastric biopsies and tumors for co-culture experiments.
  • Utilized NanoString Digital Spatial Profiling (DSP) to analyze immune markers in patient tissues.
  • Co-cultured PDOs with autologous immune cells, including PMN-MDSCs, to assess immunotherapy response.

Main Results:

  • DSP identified immunosuppressive MDSCs (Arg1, CD66b, VISTA, IDO1) in gastric tumors.
  • PDO/immune cell co-cultures showed PD-L1+ organoids were resistant to nivolumab with PMN-MDSCs.
  • PMN-MDSC depletion sensitized organoids to anti-PD-1/PD-L1 therapy; rapamycin inhibited pS6K, Gli2, and PD-L1 expression.

Conclusions:

  • PDO/immune cell co-cultures effectively model MDSC immunosuppressive functions in the gastric tumor microenvironment.
  • The mTOR pathway is a key mediator of GLI-induced PD-L1 expression in gastric cancer.
  • Targeting the mTOR/GLI/PD-L1 axis presents a potential strategy to enhance gastric cancer immunotherapy.

Related Concept Videos

Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.3K